Cancer screening

FemTech Company MobileODT awarded prestigious National Cancer Institute (NCI) grant

75th United States Congress, National Cancer Institute, Cancer, Cancer screening, Cervical cancer, Medical specialties, Clinical medicine
Wednesday, January 20, 2021 - 4:22pm

TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- MobileODT , a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million.

Key Points: 
  • TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- MobileODT , a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million.
  • This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI's goal of reducing suffering and death due to cancer.
  • This grant is a tribute to the groundbreaking advances of MobileODT as an innovative company commercializing a novel cervical cancer screening technology utilizing complex machine learning (ML) and artificial intelligence (AI) algorithms.
  • "We are honored to receive such a prestigious grant, especially from National Cancer Institute.

FDA Approves Seno Medical’s Ground-Breaking Breast Cancer Diagnostic Technology

Medical imaging, Medical physics, Breast imaging, Breast cancer, Radiology, Medicine, Clinical medicine, Applied sciences, Breast surgery, Cancer screening
Tuesday, January 19, 2021 - 3:45pm

San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions.

Key Points: 
  • San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions.
  • The companys Imagio Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may - or may not - require more invasive diagnostic evaluation.
  • The companys OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
  • Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe

Other Health, Research, General Health, Oncology, Medical devices, Genetics, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Medicine, Clinical medicine, Branches of biology, Genomics, Helmy Eltoukhy, Cancer screening, Biopsy, Liquid biopsy, Richard B. Lanman
Monday, January 18, 2021 - 8:00am

We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond, said Helmy Eltoukhy, Guardant Health CEO.

Key Points: 
  • We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond, said Helmy Eltoukhy, Guardant Health CEO.
  • We look forward to working together with Guardant Health to bring clinical-grade liquid biopsy genomic testing services to patients at pace and scale.
  • Guardant Healths liquid biopsy tests have been extensively used in clinical trials with over 200 peer-reviewed publications demonstrating its benefits to patients.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx and GuardantOMNI tests for advanced stage cancer patients.

Urology Care Foundation and American Urological Association send condolences to family, friends of Thomas V. Mike Miller, media reports indicate longtime president of Maryland Senate died of prostate cancer

Medical specialties, Clinical medicine, Medicine, Prostate cancer, Urology, Prostate, Cancer screening, National Prostate Health Month, Larry Goldenberg
Saturday, January 16, 2021 - 12:00pm

Prostate cancer is the second most common cancer in men, with a new case diagnosed every 2.1 minutes.

Key Points: 
  • Prostate cancer is the second most common cancer in men, with a new case diagnosed every 2.1 minutes.
  • "Prostate cancer is the second most common cancer in men, with a new case being diagnosed every 2.1 minutes," said Harris M. Nagler, MD, President of the Urology Care Foundation.
  • Talk to your Doctor about prostate cancer screening if you are age 40 to 54 years and:
    There are many treatment options for prostate cancer.
  • About the Urology Care Foundation:The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association.

New Research in JNCCN Highlights Dangerous Disparities for Life-Saving Cancer Screening

Medicine, Gynaecological cancer, Infectious causes of cancer, Clinical medicine, Medical terminology, Prevention, Cancer screening, Cervical screening, Screening, Cervical cancer, Cancer, Breast cancer
Wednesday, January 13, 2021 - 1:35pm

"These findings show we need more measures to eliminate socioeconomic-related health disparities in our communities, even where healthcare is publicly funded.

Key Points: 
  • "These findings show we need more measures to eliminate socioeconomic-related health disparities in our communities, even where healthcare is publicly funded.
  • Dr. Abdel-Rahman looked at self-reported data for 99,820 people eligible for colorectal cancer screening, 59,724 people eligible for breast cancer screening, and 46,767 in the cervical cancer screening cohort, based on Canadian guidelines from 2007 through 2016.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • 1Hall IJ, Tangka FK, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and Trends in Cancer Screening in the United States.

New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®

Medicine, Branches of biology, Health sciences, Exact Sciences, Infectious causes of cancer, Cancer screening, Colorectal cancer, Cancer, Large intestine, Preventive healthcare
Tuesday, January 12, 2021 - 7:45pm

These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.

Key Points: 
  • These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.
  • Study is among the first to evaluate the use of a colorectal cancer screening method in patients between ages of 45-49.
  • Cologuard is a U.S. Food & Drug Administration (FDA)-approved, non-invasive stool DNA test for colorectal cancer for average-risk people.
  • In September 2019, the FDA approved Cologuard for average-risk individuals beginning at age 45, expanding the Cologuard label to include this critical younger adult population.

CES 2021 Jun Zhi integrated Taiwan's top research teams to develop SAA Cancer Screening Services

National Tsing Hua University, Cancer screening, Academia Sinica, Cancer, Kaohsiung Medical University, Colorectal cancer
Tuesday, January 12, 2021 - 2:34pm

TAIPEI, Jan. 12, 2021 /PRNewswire/ -- Jun Zhi, a Taiwan-based biomedical team, developed the SAA Cancer Screening Service.

Key Points: 
  • TAIPEI, Jan. 12, 2021 /PRNewswire/ -- Jun Zhi, a Taiwan-based biomedical team, developed the SAA Cancer Screening Service.
  • Jun Zhi developed SAA Cancer Screening Services by integrating top research teams from Academia Sinica, National Tsing Hua University, National Yang-ming University, and Kaohsiung Medical University's Chung-Ho Memorial Hospital.
  • In its current stage of development, SAA Cancer Screening is able to detect gastric cancer and colorectal cancers.
  • This innovative biotech product helped convince Taiwan Tech Arena (TTA) to select JUN ZHI as one of the 100 featured Taiwanese startups showcased at CES 2021.

Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers

Medicine, Clinical medicine, Cancer screening, Liquid biopsy, Biopsy, Cancer
Tuesday, January 12, 2021 - 1:00pm

BALTIMORE, Jan. 12, 2021 /PRNewswire/ --Delfi Diagnostics, Inc., a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, has raised $100 million in Series A funding.

Key Points: 
  • BALTIMORE, Jan. 12, 2021 /PRNewswire/ --Delfi Diagnostics, Inc., a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, has raised $100 million in Series A funding.
  • "The Delfi team has a unique and groundbreaking approach to early detection of cancer," said Rishi Gupta, Partner at OrbiMed.
  • Delfi is developing a new class of liquid biopsy for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells.
  • Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types.

Therapixel receives the CE mark for its Artificial Intelligence-based software (AI) MammoScreen™

Cancer screening, Medical imaging, Breast imaging, Mammography, Projectional radiography, Medicine, Radiology, Clinical medicine
Tuesday, January 12, 2021 - 7:30am

PARIS, Jan. 12, 2021 /PRNewswire/ -- Therapixel announced today that MammoScreen has successfully obtained the CE mark.

Key Points: 
  • PARIS, Jan. 12, 2021 /PRNewswire/ -- Therapixel announced today that MammoScreen has successfully obtained the CE mark.
  • MammoScreen automatically analyzes screening mammograms and indicates suspicious mammograms and lesions to the radiologist.
  • According to the probability of malignancy and the degree of confidence of the algorithm, the software assigns a unique "MammoScreen Score" ranging from 1 to 10.
  • A clinical study conducted in 2019 and published in Radiology : AI, showed that radiologists assisted by MammoScreen have a better performance than without the software.

NEC Releases 'WISE VISION Endoscopy' in Europe and Japan

Clinical medicine, Medicine, Diagnostic gastroenterology, Medical specialties, Infectious causes of cancer, Cancer screening, Colonoscopy, Large intestine, Colorectal cancer, Endoscopy, Cancer, NEC
Tuesday, January 12, 2021 - 1:56am

TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.
  • This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
  • Colorectal cancer is the most common cancer in Japan(1), and the second most common in Europe(2).
  • NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue.